Solely dedicated to discovery & development of novel therapeutics

LegoChem Biosciences is a unique company founded by people with
expertise & enthusiasm for developing novel therapeutics.
Since our foundation in 2006 we have focused on the research and
development of ADC (Antibody-Drug Conjugate), Anti-biotics,
Anti-coagulants & Anti-cancer therapeutics based on our
proprietary platform technology LegoChemistry™.

[Press Release] LegoChem Biosciences receives US patent for its own proprietary ADC platform technology ConjuALL.
LegoChem Biosciences receives US patent for its own proprietary ADC platform technology ConjuALLTM. - DAEJEON, April 13, 2017 - LegoChem Bioscienses (“LCB”) is a biopharmaceutical company focusing on the research & development of ADCs, based in Daejeon South Korea, announced today that the Company was awarded U.S. Patent No. 14517616, entitled “ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE”. The patent illustrates the company’s ConjuALLTM technology, LegoChem’s proprietary ADC platform which enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.  This patent provides LCB comprehensive coverage in the United States for its ADC platform technology.  Dr. Yeong Soo Oh, Senior Vice President & Chief Technology Officer of LCB said, “This patent further strengthens LCB’s competitive advantage in the field of research and development of next generation ADCs. The use of our technology will address significant unmet needs of current ADC technologies. LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology. In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.   About LegoChem Biosciences LegoChem Biosciences is a biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry™ & ADC platform technology ConjuAll™.  Since its foundation in 2006, LCB has focused on the research and development of ADC (Antibody-Drug-Conjugates), antibiotics, anticoagulants and anticancer therapeutics based on its proprietary platform technologies. About ConjuAllTM ConjuAllTM is a next-generation ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. Our platform provides solutions for site-specific conjugation, linker stability and efficient payload release which are three major unmet needs in ADC development.   For LegoChem Biosciences BD enquiries Jeiwook Chae, Chief Business Development Officer Tel: +82 42 861 0688 Email: bd@legochembio.com   Media & Investors enquiries Wooshik Kim, Manager Tel: +82 70 4811 3260 Email: ir@legochembio.com  
2017.04.13
[Media Releases] Novimmune and LegoChem Biosciences enter research collaboration on antibody drug conjugate
Novimmune and LegoChem Biosciences enter research collaboration on antibody drug conjugate GENEVA, 13th February, 2017 — Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and LegoChem Biosciences (LCB) (KOSDAQ:141080), a South Korean company with a proprietary antibody drug conjugate (ADC) technology, have entered into a research collaboration to evaluate an antibody drug conjugate candidate.   LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology. In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.   “Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients”, said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.   ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells. Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.      About Novimmune   Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 130 people. More information is available on the company website at www.novimmune.com.       Contact: Adrian Mills +41 (0) 61 201 13 27 amills@novimmune.com
2017.02.13
[Press Release] LegoChem Biosciences Enters Into Research Licensing Agreement with Takeda to Develop Next-Generation Antibody-Drug Conjugate Candidates
LegoChem Biosciences Enters Into Research Licensing Agreement with Takeda to Develop Next-Generation Antibody-Drug Conjugate Candidates - DAEJEON, January 11, 2017 - LegoChem Bioscienses (“LCB”), based in Daejeon South Korea, announced today that the Company has entered into a research licensing agreement with Takeda Pharmaceuticals Company Limited (TSE:4502) (”Takeda”) to evaluate next-generation antibody drug conjugate (ADC) candidates. Through this agreement, Takeda will have access to LCB’s proprietary ADC technology, ConjuAllTM. ConjuAllTM is LCB’s proprietary next-generation ADC technology platform. Utilizing a site-specific bio-conjugation method and a stable beta-glucuronide linker, ConjuAll™ enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells. Under the terms of the agreement, the companies will focus on evaluating novel ADC candidates. Takeda will have an exclusive option to license global rights for the project results. Dr. Yong Zu Kim, President & CEO of LCB said, “We are delighted that Takeda has recognized the potential of our proprietary ADC technology to address unmet medical needs in the ADC field.  Takeda is a desirable partner for LCB as they have expertise and experience in the global commercialization of an antibody drug conjugate therapy.” Takeda signed the research licensing agreements with LCB through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc.   About LegoChem Biosciences LegoChem Biosciences is a biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry™ & ADC platform technology ConjuAll™.  Since its foundation in 2006, LCB has focused on the research and development of ADC (Antibody-Drug-Conjugates), antibiotics, anticoagulants and anticancer therapeutics based on proprietary platform technologies. About ConjuAllTM ConjuAllTM is a next-generation ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. Our platform provides solutions for site-specific conjugation, linker stability and efficient payload release which are three major unmet needs in ADC development.   MedCI LLC, a business development consulting firm, served as an advisor to LCB.   For LegoChem Biosciences BD enquiries Jeiwook Chae, Chief Business Development Officer Tel: +82 42 861 0688 Email: bd@legochembio.com   Media & Investors enquiries Wooshik Kim, Manager Tel: +82 70 4811 3260 Email: ir@legochembio.com  
2017.01.11
LegoChem Biosciences corporate IR presentation (Nov. 2016)

For recent corporate status and research updates as of Nov 2016, please download the file below.

 

 

About LegoChem Biosciences

 

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).   

LCB_Corporate_Presentation_EN_v20161123.pdf 2016.11.01
LegoChem Biosciences Corporate Presentation (Sep 2015)

For recent corporate status and research updates as of Sep 2015, please download the file below.

 

 

About LegoChem Biosciences

 

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).   

LCB_Corporate_presentation_v2015-09-02_clean.pdf 2015.09.10
LegoChem Biosciences Corporate Presentation (May 2014)

For recent corporate status and research updates, please download the file below.

 

 

About LegoChem Biosciences

 

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).   

LCB_Corporate_presentation_May_2014.pdf 2014.05.08